Efficacy of Passive Immunization with IgY Antibodies to a 58-kDa<i>H. pylori</i>Antigen on Severe Gastritis in BALB/c Mouse Model

Attallah, Abdelfattah M.; Abbas, Ayman T.; Ismail, Hisham; Abdel-Raouf, Mohamed; El-Dosoky, Ibrahim

doi:10.1080/15321810903187922

Cited by 19 publications

(12 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such anti-bacterial and anti-inflammatory effects of IgY seem to be higher than the efficacy of IgY-Hp that exhibited 50-60% anti-inflammatory activity at 180 mg/kg in a gerbil model [35]. Furthermore, the efficacy of IgY was superior to the H. pylori -elimination ratio (70%) of IgY-Hp58 specific for 58-kDa H. pylori (Hp) antigen [38]. On the other hand, it was reported that urease-specific IgY significantly attenuated gastric inflammation of gerbils fed at a concentration of 25 mg/g diet [39].…”

Section: Discussionmentioning

confidence: 99%

Anti-Helicobacter pylorieffects of IgY from egg york of immunized hens

et al. 2012

View full text Add to dashboard Cite

Effects of egg york containing IgY specific for Helicobacter pylori on the bacterial growth and intragastric infection were investigated in comparison with a proton-pump inhibitor pantoprazole. For in vitro anti-bacterial activity test, H. pylori (1×10 8 CFU/mL) was incubated with a serially diluted IgY for 3 days. As a result, IgY fully inhibited the bacterial growth at 16 mg/mL, which was determined to a minimal inhibitory concentration. In vivo elimination study, male C57BL/6 mice were infected with the bacteria by intragastric inoculation (1×10 8 CFU/mouse) 3 times at 2-day intervals, and 2 weeks later, orally treated twice a day with 50, 100, 200 or 500 mg/kg IgY for 18 days. After the final administration, biopsy sample of the gastric mucosa was assayed for the bacterial identification via urease, oxidase, catalase, nitrate reduction and H 2 S tests in addition to microscopic examination for mucosal inflammation. In CLO kit test, 75, 50, 12.5 and 12.5% of the animals revealed positive reaction following treatment with 50, 100, 200 and 500 mg/kg IgY, respectively, resulting in a superior efficacy at 200 mg/kg than 30 mg/kg pantoprazole that displayed 75% elimination. The CLO test results were confirmed by bacterial identification. Microscopic examination revealed that H. pylori infection caused severe gastric mucosal inflammation, which were not observed in the CLO-negative mice following treatment with IgY or pantoprazole. Taken together, IgY inhibited the growth of H. pylori , and improved gastritis and villi injuries by eliminating the bacteria from the stomach. The results indicate that IgY could be a good candidate overcoming tolerance of antibiotics for the treatment of H. pylori -mediated gastric ulcers.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-Helicobacter pylorieffects of IgY from egg york of immunized hens

et al. 2012

View full text Add to dashboard Cite

show abstract

“…[56][57][58] Our group previously developed a reliable murine model for H. pylori infection. 59 In addition, we developed IgY antibodies in chickens that target a pathogenic H. pylori strain and used these antibodies to treat infected mice. Passively immunized mice had a significantly lower degree of infection and gastritis than unimmunized animals.…”

Section: Immunoglobulin Y Antibodiesmentioning

confidence: 99%

“…Passively immunized mice had a significantly lower degree of infection and gastritis than unimmunized animals. 59 Oral administration of anti-H. pylori IgY can be used a complementary therapy combined with routine antibiotic therapy. 60…”

Section: Immunoglobulin Y Antibodiesmentioning

confidence: 99%

IgY antibodies for the immunoprophylaxis and therapy of respiratory infections

Abbas

El‐Kafrawy

Sohrab

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Emergence of drug resistance among the causative organisms for respiratory tract infections represents a critical challenge to the global health care community. Further, although vaccination can prevent disease, vaccine development is impeded by several factors. Therefore, novel approaches to treat and manage respiratory infections are urgently needed. Passive immunization represents a possible alternative to meet this need. Immunoglobulin Y antibodies (IgYs) from the yolk of chicken eggs have previously been used against bacterial and viral infections in human and animals. Their advantages include lack of reaction with mammalian Fc receptors, low production cost, and ease of extraction. Compared to mammalian IgGs, they have higher target specificity and greater binding avidity. They also possess remarkable pathogen-neutralizing activity in the respiratory tract and lungs. In this review, we provide an overview of avian IgYs and describe their potential therapeutic applications for the prevention and treatment of respiratory infections.

show abstract

“…This approach mimics naïve protection in humans and has been shown to be effective in the prevention and treatment of a variety of pathogens, such as Rotavirus, Clostridium difficile , and Campylobacter jejuni [ 17 – 21 ]. Many animal studies have shown that bovine antibody-containing milk against H. pylori reduces bacterial load, thus preventing and even eradicating H. pylori infection [ 22 – 25 ]. However, the available clinical studies of bovine antibodies in milk have not shown H. pylori eradication [ 26 – 29 ].…”

Section: Introductionmentioning

confidence: 99%

The clearance effect of bovine anti-Helicobacter pylori antibody-containing milk in O blood group Helicobacter pylori-infected patients: a randomized double-blind clinical trial

Zhang

Zhou

et al. 2015

J Transl Med

View full text Add to dashboard Cite

BackgroundThe failure in standard triple therapy has recently increased to high levels in China, primarily because of insufficient patient compliance, antimicrobial resistance, and high costs. Effective prevention and eradication of Helicobacter pylori (H. pylori) by artificial passive immunization with orally administered bovine antibodies in the milk has been demonstrated in many animal studies, but the clinical studies that are available have shown no H. pylori eradication. This study was to evaluate the efficacy and safety of orally administered bovine anti-H. pylori antibodies for the clearance of H. pylori infecting O blood group subpopulations.MethodsTwo local epidemic H. pylori strains that were prevalent locally were screened and then used to immunize dairy cows. After confirmation of the presence of anti-H. pylori polyclonal antibodies in the milk by enzyme-linked immunosorbent assay, the milk was subsequently defatted and processed into sterile milk by pasteurization. This study was designed as a double-blind placebo-controlled randomized clinical trial. Our 61 H. pylori-infected O blood group subjects were assigned to two groups; 31 subjects were treated with bovine milk containing antibodies and 30 subjects with the placebo. The medication-based study was continued for 28 days. Subjects were followed up for 56 days. The effect was assessed by the C-14 urea breath test (UBT). SPSS 17.0 software for Windows was used to analyze the data.ResultsOf the 61 subjects enrolled, 58 completed the protocol. One volunteer in the antibodies group and two volunteers in the control group dropped out. Of the 30 antibody-treated subjects, 13 became UBT negative, whereas none of the 30 of the placebo-treated subjects became UBT negative after the medication. Of 13 UBT negative patients, 3 became positive again at the end of the follow-up. Both intention to treat and per-protocol analysis indicated a significant difference in the clearance rate of infected patients between the groups treated with bovine antibody-containing milk and the placebo (P = 0.001, P < 0.05) and no significant difference in adverse effects (P > 0.05 all).ConclusionsBovine antibody-based oral immunotherapy appears to be safe and has a significant clearance effect on intragastric H. pylori that infects O blood group adults.Trial registration: ChiCTR-TRC-14005212.

show abstract

Efficacy of Passive Immunization with IgY Antibodies to a 58-kDaH. pyloriAntigen on Severe Gastritis in BALB/c Mouse Model

Cited by 19 publications

References 45 publications

Anti-Helicobacter pylorieffects of IgY from egg york of immunized hens

Anti-Helicobacter pylorieffects of IgY from egg york of immunized hens

IgY antibodies for the immunoprophylaxis and therapy of respiratory infections

The clearance effect of bovine anti-Helicobacter pylori antibody-containing milk in O blood group Helicobacter pylori-infected patients: a randomized double-blind clinical trial

Contact Info

Product

Resources

About